Paliperidone Palmitate
Common brands: Invega Sustenna, Invega Trinza, Invega Hafyera, Erzofri Extended-Release, Risperdal
Top reporter: Janssen Pharmaceuticals, Inc.
Atypical Antipsychotic [EPC]Benzodiazepine [EPC]Anti-epileptic Agent [EPC]Mood Stabilizer [EPC]Nonsteroidal Anti-inflammatory Drug [EPC]
31,425
Total Reports
11,547
Serious Reports
1,160
Death Reports
30
Reported Reactions
Death Report Ratio: Moderate (3.69%)
Patient Demographics
Reported Adverse Reactions (30)
Side effects reported in FDA adverse event reports for Paliperidone Palmitate.
| # | Reaction | Reports | % of Total |
|---|---|---|---|
| 1 | OFF LABEL USE | 3,111 | |
| 2 | DRUG INEFFECTIVE | 2,183 | |
| 3 | HOSPITALISATION | 1,775 | |
| 4 | WEIGHT INCREASED | 1,630 | |
| 5 | DRUG DOSE OMISSION | 1,417 | |
| 6 | PRODUCT DOSE OMISSION ISSUE | 1,365 | |
| 7 | SCHIZOPHRENIA | 1,102 | |
| 8 | GYNAECOMASTIA | 1,085 | |
| 9 | CONDITION AGGRAVATED | 979 | |
| 10 | TREATMENT NONCOMPLIANCE | 935 | |
| 11 | BLOOD PROLACTIN INCREASED | 927 | |
| 12 | PSYCHOTIC DISORDER | 891 | |
| 13 | INCORRECT DOSE ADMINISTERED | 870 | |
| 14 | INAPPROPRIATE SCHEDULE OF DRUG ADMINISTRATION | 785 | |
| 15 | THERAPEUTIC RESPONSE DECREASED | 750 | |
| 16 | INAPPROPRIATE SCHEDULE OF PRODUCT ADMINISTRATION | 716 | |
| 17 | GALACTORRHOEA | 693 | |
| 18 | INJECTION SITE PAIN | 682 | |
| 19 | HALLUCINATION, AUDITORY | 668 | |
| 20 | PRODUCT USE IN UNAPPROVED INDICATION | 644 | |
| 21 | INSOMNIA | 621 | |
| 22 | DEATH | 613 | |
| 23 | DEPRESSION | 590 | |
| 24 | ANXIETY | 580 | |
| 25 | ADVERSE EVENT | 524 | |
| 26 | INJECTION SITE NODULE | 520 | |
| 27 | FATIGUE | 519 | |
| 28 | AKATHISIA | 518 | |
| 29 | TREMOR | 516 | |
| 30 | SEDATION | 494 |
Important Disclaimer
FDA adverse event reports are submitted voluntarily and do not prove causation. A reported reaction does not mean the drug caused it. Drugs with more users naturally have more reports. Always consult your doctor or pharmacist before making medication decisions.